October 26, 2026
Bonus Content: Apple Sold Out the iPhone Duo Fast. November 2 Is the Test.
Dear Investor,
I want to ask you a strange question.
What happens when the public turns against the products of a giant industry… but the world still needs the job those products perform?
That is not a theoretical question.
We have watched versions of this story before. For years, tobacco appeared untouchable. It was profitable, familiar and woven into everyday American life.
Then the pressure started building.
Scientific concern. Public scrutiny. Lawsuits. Regulation. A slow but unmistakable change in what consumers would accept.
Tobacco demand could fall because people could stop smoking.
But people cannot simply stop controlling mosquitoes, termites, roaches, ticks and the pests that threaten homes, businesses, food and public health.
That is what makes today’s pesticide story so interesting.
If traditional chemical products face mounting pressure, the need does not go away. The money does not necessarily disappear. It may begin moving toward a different kind of solution.
And quietly – well outside the spotlight of most Wall Street research – one small private company has spent years developing botanical pest-control products designed for this changing market.
That company is Med-X, Inc. It has reserved MXRX for possible use following a successful future Nasdaq listing.
I am not asking you to buy a stock. I am asking you to examine a question before the answer becomes obvious to everyone else:
If pesticides are entering their “tobacco moment,” where could the demand go next?
We prepared a detailed report that follows the entire story – from the historical comparison, to the unavoidable demand for pest control, to the botanical category and the company attempting to build inside it.
The report is long. Deliberately so. It gives you the argument, the counterarguments and the facts you should investigate for yourself.
Click here now to read “Are Pesticides the New Tobacco?”
You may agree with the comparison. You may reject it. Either way, this is a market transition worth understanding.
Sincerely,
The Editors
National Investor Network
P.S. The most consequential changes often look gradual – until suddenly they do not. Read the full investor letter here and decide for yourself whether pest control is approaching one of those moments.
|
Apple Sold Out the iPhone Duo Fast. November 2 Is the Test.
Apple’s first foldable phone sold out much of its initial store inventory on October 23, the day it went on sale. Online delivery windows slid to late January within minutes of preorders opening the previous week. The company called demand “nothing short of extraordinary.” The stock touched a record $351.73 on Friday before closing at $347.73, briefly pushing Apple past Nvidia as the world’s most valuable public company.
The iPhone Duo starts at $1,999 and reaches $3,199 for the 2TB configuration. It is also an early challenge for Apple’s new CEO John Ternus, who unveiled the phone in September, shortly after taking charge on September 1. Marking the company’s most radical reinvention in the iPhone’s nearly two-decade history, the Duo is a major bet that Apple can establish itself in a category that has remained a niche so far.
The market math is straightforward. IDC expects Apple to ship more than 17 million foldable iPhones by 2027, capturing roughly 40% of the global foldables market. Worldwide smartphone shipments are on pace for a 16.7% decline in 2026 as the memory crisis hits full force, according to IDC, while total market value still grows. IDC and other industry trackers expect foldables to be a relative bright spot, with Apple’s entry a meaningful swing factor for the category.
The supply picture already forced Apple’s hand. Apple has reportedly asked suppliers to raise Duo orders by 30%, with delivery dates stretching to late January. That kind of constraint matters for how Q1 fiscal 2027 revenue shapes up, but it doesn’t help the number that arrives November 2.
Apple reports quarterly earnings on November 2, but those results will not include Duo sales because the period concluded at the end of September. The report will instead reflect early sales of iPhone 18 Pro and Pro Max models, which debuted September 18. Wall Street is split on what that means. Wedbush’s Dan Ives sees a path to $400; JPMorgan holds at $360; Loop Capital cut its target to $330 with a Hold rating.
The tension is real. Early reviews are mixed, highlighting design strengths but some functional compromises. Several prominent reviewers recommended against the Duo for many Apple customers. A $2,000 device built on a folding display will always carry a different risk profile than a mass-market phone.
The risk profile of a $2,000 device extends beyond Apple’s own balance sheet. Apple’s $30 billion-plus chip commitment to Broadcom ties a key supplier’s revenue trajectory directly to the Duo’s commercial success.
The November 2 report sets the baseline. Fiscal Q4 numbers will tell investors how much early iPhone 18 demand Apple captured before the Duo reshaped expectations. Guidance for the December quarter, the first one where Duo sales actually count, is where this trade lives or dies. The sellout is a signal. The margin commentary next Thursday will be the answer.
